{
    "Trade/Device Name(s)": [
        "ALPCO Calprotectin Chemiluminescence ELISA",
        "ALPCO Easy Stool Extraction Device"
    ],
    "Submitter Information": "ALPCO",
    "510(k) Number": "K191807",
    "Predicate Device Reference 510(k) Number(s)": [
        "K160447"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NXO"
    ],
    "Summary Letter Date": "October 25, 2019",
    "Summary Letter Received Date": "July 5, 2019",
    "Submission Date": "July 3, 2019",
    "Regulation Number(s)": [
        "21 CFR 866.5180"
    ],
    "Regulation Name(s)": [
        "Fecal Calprotectin Immunological Test System"
    ],
    "Analyte Class(es)": [
        "immunology"
    ],
    "Analyte(s)": [
        "Fecal Calprotectin"
    ],
    "Specimen Type(s)": [
        "Stool"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Chemiluminescent plate reader",
        "96 well microtiter plate"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent enzyme-linked immunosorbent assay (ELISA)",
        "Sandwich ELISA"
    ],
    "Methodologies": [
        "Immunological assay",
        "Chemiluminescent detection",
        "Sandwich ELISA"
    ],
    "Submission Type(s)": [
        "Assay",
        "Device",
        "Extraction device"
    ],
    "Document Summary": "FDA 510(k) summary for ALPCO Calprotectin Chemiluminescence ELISA and Easy Stool Extraction Device for quantitative measurement of fecal calprotectin as a marker of intestinal inflammation.",
    "Indications for Use Summary": "Intended for quantitative measurement of fecal calprotectin in human stool to aid in diagnosis of inflammatory bowel disease (IBD), specifically Crohn\u2019s disease and ulcerative colitis, and to differentiate IBD from irritable bowel syndrome (IBS), in conjunction with other clinical and laboratory findings; the extraction device is for stool specimen preparation for this test.",
    "fda_folder": "Immunology"
}